Weiss Multi-Strategy Advisers’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-7,880	Closed	-$253K	–	683
2016 Q4	$253K	Buy	7,880 +3,177	+68%	+$135K	0.01%	373
2016 Q3	$235K	Buy	4,703 +533	+13%	+$22.1K	0.01%	389
2016 Q2	$177K	Sell	4,170 -2,821	-40%	-$154K	0.01%	381
2016 Q1	$460K	Hold	6,991	–	–	0.02%	395
2015 Q4	$435K	Buy	6,991 +509	+8%	+$35.8K	0.03%	313
2015 Q3	$434K	Buy	+6,482	New	+$529K	0.02%	330
2015 Q1	–	Sell	-1,271	Closed	-$113K	–	573
2014 Q4	$113K	Sell	1,271 -3,813	-75%	-$278K	﹤0.01%	392
2014 Q3	$351K	Hold	5,084	–	–	0.01%	466
2014 Q2	$292K	Sell	5,084 -2,542	-33%	-$129K	0.01%	655
2014 Q1	$302K	Sell	7,626 -8,897	-54%	-$381K	0.01%	813
2013 Q4	$693K	Buy	16,523 +6,355	+63%	+$184K	0.02%	524
2013 Q3	$303K	Buy	10,168 +2,542	+33%	+$88.9K	0.01%	652
2013 Q2	$404K	Buy	+7,626	New	+$334K	0.01%	511

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Weiss Multi-Strategy Advisers's MACK Position: Q1 2017 in Review

Weiss Multi-Strategy Advisers sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2017, closing a stake of 7,880 shares — an estimated $253K sold.

Weiss Multi-Strategy Advisers first reported a position in MACK in Q2 2013 and held it in 13 quarters. The position peaked at $693K in Q4 2013. 116 funds tracked by Wall St. Rank hold MACK as of Q1 2017.

Weiss Multi-Strategy Advisers reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 7,880 Merrimack Pharmaceuticals, Inc. shares in Q1 2017, an estimated $253K.
Weiss Multi-Strategy Advisers first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 13 quarters.
Weiss Multi-Strategy Advisers's Merrimack Pharmaceuticals, Inc. position peaked at $693K in Q4 2013.
116 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2017.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2017, filed 15 May 2017.